Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Osamu IWASE"'
Autor:
Osamu Iwase, Hideaki Takenaka
Publikováno v:
Energy Science & Engineering, Vol 10, Iss 9, Pp 3471-3492 (2022)
Abstract This study describes the estimation of solar radiation from photovoltaic (PV) power generation in smart streetlights (SSL) with a heat transfer model. The distribution of solar radiation is important for managing PV power generation. In part
Externí odkaz:
https://doaj.org/article/aca2425ed01c4e44bba98b739d724bdd
Autor:
Naoto Takahashi, Kaichi Nishiwaki, Chiaki Nakaseko, Nobuyuki Aotsuka, Koji Sano, Chikako Ohwada, Jun Kuroki, Hideo Kimura, Michihide Tokuhira, Kinuko Mitani, Kazuhisa Fujikawa, Osamu Iwase, Kohshi Ohishi, Fumihiko Kimura, Tetsuya Fukuda, Sakae Tanosaki, Saori Takahashi, Yoshihiro Kameoka, Hiroyoshi Nishikawa, Hisashi Wakita
Publikováno v:
Haematologica, Vol 103, Iss 11 (2018)
The purpose of this trial was to evaluate the efficacy of 2-year consolidation therapy with nilotinib, at a dose of 300 mg twice daily, for achieving treatment-free remission in chronic myeloid leukemia patients with a deep molecular response (BCR-AB
Externí odkaz:
https://doaj.org/article/d270522d9d4c488f9dc35f3bb6c9b3ce
Autor:
Michihide Tokuhira, Jun Kuroki, Osamu Iwase, Fumihiko Kimura, Tetsuya Fukuda, Naoto Takahashi, Koji Sano, Kaichi Nishiwaki, Kinuko Mitani, Kohshi Ohishi, Sakae Tanosaki, Hisashi Wakita, Saori Takahashi, Chikako Ohwada, Kazuhisa Fujikawa, Hiroyoshi Nishikawa, Chiaki Nakaseko, Yoshihiro Kameoka, Nobuyuki Aotsuka, Hideo Kimura
Publikováno v:
Haematologica
The purpose of this trial was to evaluate the efficacy of 2-year consolidation therapy with nilotinib, at a dose of 300 mg twice daily, for achieving treatment-free remission in chronic myeloid leukemia patients with a deep molecular response (BCR-AB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be3ed0a369e410006c844d9364125022
https://doi.org/10.3324/haematol.2018.194894
https://doi.org/10.3324/haematol.2018.194894
Autor:
Hiroyuki Miura, Osamu Iwase, E. Nakashima, Y. Ogawa, Nobuyuki Koyama, Y. Umebayashi, K. Kishida, T. Kondo, Y. Watanabe, Hidenobu Takahashi
Publikováno v:
BMC Pulmonary Medicine
BMC Pulmonary Medicine, Vol 18, Iss 1, Pp 1-7 (2018)
BMC Pulmonary Medicine, Vol 18, Iss 1, Pp 1-7 (2018)
Background Nivolumab, an anti-programmed cell death-1 (PD-1) monoclonal antibody used as an immune checkpoint inhibitor, is commonly employed for its anti-tumor effects against various types of malignant tumors. However, its administration is complic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e17fc568e974873da4a6585cbcbc26b8
https://doi.org/10.1186/s12890-018-0592-x
https://doi.org/10.1186/s12890-018-0592-x
Autor:
Atsushi Shinagawa, Shingo Yano, Eri Matsuki, Yasuji Kozai, Koiti Inokuchi, Shinichiro Okamoto, Chikashi Yoshida, Shin Fujisawa, Osamu Iwase, Yukari Shirasugi, Hisashi Sakamaki, Jin Takeuchi, Takashi Kumagai, Koji Oba, Hisashi Wakita, Yoshihiro Hatta, Junichi Sakamoto, Kazuteru Ohashi
Publikováno v:
Journal of Clinical and Experimental Hematopathology. 54:197-204
Dasatinib is a BCR-ABL kinase inhibitor with improved potency compared with imatinib, for which efficacy and safety in imatinib-resistant and imatinib-intolerant patients with chronic myelogenous leukemia (CML) have been established. Here, an open-la
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5877ece3358dafd640be2c8cef4369d
https://doi.org/10.3960/jslrt.54.197
https://doi.org/10.3960/jslrt.54.197
Autor:
Naoyuki Yahata, Osamu Iwase, Hiroshi Iwama, Tetsuzo Tauchi, Yoshikazu Kawanishi, Hiromi Serizawa, Kazuma Ohyashiki
Publikováno v:
Leukemia & Lymphoma. Sep2000, Vol. 39 Issue 1/2, p203. 5p. 3 Black and White Photographs, 1 Diagram.
Autor:
Osamu Iwase, Takashi Kumagai, Koji Oba, Kazuteru Ohashi, Hisashi Wakita, Junichi Sakamoto, Yasuji Kozai, Atsushi Shinagawa, Shinichiro Okamoto, Yukari Shirasugi, Koiti Inokuchi, Chikashi Yoshida, Jin Takeuchi, Shin Fujisawa, Shingo Yano, Kaichi Nishiwaki, Hisashi Sakamaki, Eri Matsuki
Publikováno v:
International Journal of Hematology. 99:41-52
Lymphocytosis in response to dasatinib for chronic myelogenous leukemia (CML) may be associated with favorable response. However, it occurs at varying times and in a limited subset of patients. To identify early clinical markers for favorable respons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a85e778c58e58387a0c8abdd46e9005
https://doi.org/10.1007/s12185-013-1483-9
https://doi.org/10.1007/s12185-013-1483-9
Autor:
Akihiro Nakajima, Haruko Yokoyama, Osamu Iwase, Hironori Nakamura, Yasuhiko Yamada, Kiyoshi Okuyama, Koichi Yoshimoto
Publikováno v:
Biological and Pharmaceutical Bulletin. 36:780-787
5-HT3 receptor antagonists are widely used for prevention of chemotherapy-induced nausea and vomiting, though their antiemetic effects vary among patients. We investigated a method for evaluation of antiemetic effects in individual patients. We used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5ef41a887f7078c0a70595381944f37
https://doi.org/10.1248/bpb.b12-00946
https://doi.org/10.1248/bpb.b12-00946
Autor:
Kosuke Kishida, Eiji Nakajima, Hiroyuki Miura, Osamu Iwase, Yasutaka Watanabe, Nobuyuki Koyama, Hidenobu Takahashi
Publikováno v:
Annals of Oncology. 28:ix85-ix86
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26e7f896e87ec217931518ee599b6304
https://doi.org/10.1093/annonc/mdx697.051
https://doi.org/10.1093/annonc/mdx697.051
Publikováno v:
YAKUGAKU ZASSHI. 128:649-655
To evaluate the antiemetic effects of 5-HT(3) receptor antagonists, we investigated the relationship between condition of food intake and occurrence of nausea and vomiting. We collected data such as sex, age, disease, combination of steroids and cent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d20ad3fd3b1341203af4ce3a050914bd
https://doi.org/10.1248/yakushi.128.649
https://doi.org/10.1248/yakushi.128.649